What We Learned from the Super BAP
Bottom Line: |
The June 2026 Super BAP signaled the Defense Health Agency's pivot toward biosimilar baselines, class-specific supply chain contracting, and new net-value pricing, |
The Department of Defense (DoD) Uniform Formulary Beneficiary Advisory Panel (UF BAP or commonly referred to as just the BAP) reconvened in late June 2026 to systematically review a backlog of drug decisions spanning eight consecutive Pharmacy and Therapeutics (P&T) Committee cycles. This high-volume session cleared pending Defense Health Agency (DHA) formulary updates. Ultimately, this consolidated rollout offered a rare opportunity to gain larger insights into the DHA’s strategic evolution in three clear shifts:
1. Broadened Therapeutic Equivalency
The most significant trend across these eight cycles is how systematically the DHA expanded its definition of therapeutic equivalence. Historically, complex biologic or specialty classes had a degree of pricing insulation because each asset was evaluated as distinct and non-identical. The deliberate pivot toward evaluating complex products against baseline class standards forced direct cost-effectiveness comparisons between assets that may have been traditionally reviewed as unique. By ensuring a product met the clinical baseline standard for safety and efficacy, but then including all baseline products in the price and net value comparisons, the DHA increased the number of products directly competing for formulary placement.
Takeaway:
Clinical differentiation or a novel mechanism of action alone does not in and of itself protect an asset from non-preferred status or exclusion. The clinical dossier will establish the baseline safety and therapeutic relevance but will not determine final placement on its own.
2. Multi-Source Portfolio
The BAP review highlighted a shift toward the DHA tailoring its portfolio strategy based on class-specific dynamics. In high-demand or shortage-prone categories, the agency is moving towards a split or blended portfolio model to enhance supply chain resilience by generally not allowing a single manufacturer to win the full class. By actively expanding its vendor base across multiple manufacturers in these key categories, the agency can sustain needed volume, eliminate bottlenecks, and prevent single-point distribution failures. To note, in highly stable markets, the agency will continue to leverage a single-winner approach to achieve maximum price concessions.
Takeaway:
In supply-sensitive categories, the risk-sharing model creates the potential for manufacturers to capture a stable slice of the multi-award pie and the opportunity for predictable utilization within this health system.
3. A New Approach to Cost Containment
The rapid, simultaneous preference given to biosimilars across multiple therapeutic classes during the super BAP highlights the DHA making a deliberate shift toward cost containment, signaling that biosimilars are now firmly established as a primary standard of care. Executing this cross-category transition that establishes lower-cost biologics as the baseline is a structural development.
Takeaway:
Long-term success within complex specialty classes for this market will shift to proactive lifecycle management, competitive baseline pricing, and demonstrating total economic value.
